2016年英国再生障碍性贫血诊治指南解读被引量：9

Interpretation of the 2016 edition of guidelines for the diagnosis and treatment of aplastic anemia in UK

导出

摘要再生障碍性贫血是一种不明原因导致T淋巴细胞免疫亢进进而损伤自身造血细胞引起的正常造血衰竭性疾病。其病因和发病机制尚未完全明确,治疗起效慢、效果差,患者可出现严重的感染、出血和贫血,甚至危及生命。文章对2016年英国再生障碍性贫血诊治指南做一解读,以供参考。 Aphstic anemia （AA） is a hematologic disease, which has been recognized as an immune-mediated destruction ofhematopoietic cells caused by active T lymphocytes with unknown causes. The exact etiology and pathogenesisofAA is still unknown, leading to bad treatment effect and high mortaliy.Death of AA is usually due to complications such as infection, hemorrhage, or severe anemia.This article mainly makes an interpretation of the ＂Guidelines for the diagnosis and treatment of aplastic anaemia （2016）＂for reference.

作者刘春燕付蓉

机构地区天津医科大学总医院血液科

出处《中国实用内科杂志》 CAS CSCD 北大核心 2017年第8期712-715,共4页 Chinese Journal of Practical Internal Medicine

关键词再生障碍性贫血指南解读 aplastic anemia guideline interpretation

分类号 R556 [医药卫生—血液循环系统疾病]

引文网络
相关文献

参考文献1

1施均,常红,张莉,邵英起,聂能,张静,黄金波,张丽,唐旭东,全日成,郑春梅,肖海燕,胡明辉,胡令彦,刘锋,周永明,郑以州,张凤奎.地拉罗司对伴有铁过载的再生障碍性贫血患者的祛铁疗效及安全性——一项单臂、多中心、前瞻性临床研究[J].中华血液学杂志,2016,37(1):1-6. 被引量：5

二级参考文献16

1Fleming RE, Ponka E Iron overload in human disease [J]. N Engl J Med, 2012, 366 (4): 348-359. doi: 10.1056/NEJM- ra1004967.
2Brittenham GM. Iron-chelation therapy for transfusional iron overload [J]. N Engl J Med, 2011, 364 (2): 146-156. doi: 10.1056/NEJMct 1004810.
3Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusion- al iron overload [J]. Blood, 2012, 120 (18): 3657-3669. doi: 10.1182/blood-2012-05-370098.
4Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of defer- asirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia[ J]. Blood, 2006, 107(9): 3455-3462.
5Vichinsky E, Onyekwere O comparison of deferasirox Porter J, et al. A randomised versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease [J]. Br J Haematol, 2007, 136(3 ): 501-508.
6Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias [J]. Haematologica, 2010, 95 (4): 557-566. doi: 10.3324/haematol.2009.014696. t, 2007: 19-23.
7Lee JW, Yoon SS, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial [ J ]. Blood, 2010, 116 (14) : 2448-2454. doi: 10.1182/blood-2010-01-261289.
8Lee SE, Yahng SA, Cho BS, et al. Improvement in hematopoie- sis after iron chelation therapy with deferasirox in patients with aplastic anemia[J]. Acta Haematol, 2013, 129(2): 72-77. doi: 10.1159/000342772.
9Quarta A, Melpignano A, Quarta G. Oral iron chelator defera- sirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia [J]. Acta Haematol, 2011, 125 (4): 219- 221. doi: 10.1159/000322802.
10. Lee JW, Jang PS, Chung NG, et al. Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia [J]. Pediatr Hematol Oncol, 2011, 28 (8): 718- 720. doi: 10.3109/08880018.2011.615050.